HOBOKEN, N.J.--(BUSINESS WIRE)--NICE Actimize, a NICE (NASDAQ: NICE) business, today confirmed that NICE Actimize was named the winner of the 2024 Datos Insights Fraud & AML Impact Award for Best AML ...

Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment ...

The Financial Crimes Enforcement Network (FinCEN) and the federal banking agencies recently published the long-awaited notice of proposed rulemaking for the anti-money laundering/countering the ...

Earlier this summer, the U.S. Department of the Treasury’s Financial Crimes Enforcement Network (FinCEN) issued a Proposed Rule revising its regulations under the Bank Secrecy Act (BSA) requiring ...

HOBOKEN, N.J.--(BUSINESS WIRE)--NICE Actimize, a NICE (NASDAQ: NICE) business, today announced that TF Bank, Sweden, has chosen NICE Actimize AML Essentials, a cloud-based offering of end-to-end ...

A total payment of approximately US$3.09 billion, largely covered by previous provisions of US$3.05 billion. Requirements to remediate the Bank’s U.S. AML program, broadly aligned to its existing ...

- Milestone triggered by dosing of first patient in frontline AML Phase 3 clinical program- SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia ...

RIAs should act now to comply with the final anti-money laundering rule, even if it is altered or extended past its current enforcement deadline of Jan. 1, 2028. The rule from the Treasury ...

HOUSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for ...